fluphenazine has been researched along with Weight Gain in 4 studies
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| "We describe the case of a 39-year-old patient with schizophrenia who developed worsening of glucose metabolism during treatment with two different atypical antipsychotics, clozapine and quetiapine." | 3.73 | Importance of oral glucose tolerance test in patient with schizophrenia. ( Aukst-Margetić, B; Badanjak, A; Margetić, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kroeze, WK | 1 |
| Hufeisen, SJ | 1 |
| Popadak, BA | 1 |
| Renock, SM | 1 |
| Steinberg, S | 1 |
| Ernsberger, P | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Roth, BL | 1 |
| Covell, NH | 1 |
| McEvoy, JP | 1 |
| Schooler, NR | 1 |
| Stroup, TS | 1 |
| Jackson, CT | 1 |
| Rojas, IA | 1 |
| Essock, SM | 1 |
| Margetić, B | 1 |
| Aukst-Margetić, B | 1 |
| Badanjak, A | 1 |
| Baptista, T | 1 |
| Martinez, M | 1 |
| Lacruz, A | 1 |
| Arellano, A | 1 |
| Mendoza, S | 1 |
| Beaulieu, S | 1 |
| Hernández, L | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 1 |
| Vargas, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
2 trials available for fluphenazine and Weight Gain
| Article | Year |
|---|---|
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti | 2007 |
2 other studies available for fluphenazine and Weight Gain
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum | 2003 |
Importance of oral glucose tolerance test in patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Fluphenazine; Glucose Tolerance T | 2005 |